Premium
Immune checkpoint blockade in renal cell carcinoma
Author(s) -
Rappold Phillip M.,
Silagy Andrew W.,
Kotecha Ritesh R.,
Hakimi Ari A.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26339
Subject(s) - medicine , blockade , renal cell carcinoma , immune checkpoint , oncology , immune system , immunology , receptor
Immune checkpoint blockade (ICB) is the foundation of current first‐line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long‐lasting remissions. With the expanding arsenal of ICB‐based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC.